KR102089241B1 - 암 환자에서 면역 치료 효과를 예측하는 방법 - Google Patents

암 환자에서 면역 치료 효과를 예측하는 방법 Download PDF

Info

Publication number
KR102089241B1
KR102089241B1 KR1020180014177A KR20180014177A KR102089241B1 KR 102089241 B1 KR102089241 B1 KR 102089241B1 KR 1020180014177 A KR1020180014177 A KR 1020180014177A KR 20180014177 A KR20180014177 A KR 20180014177A KR 102089241 B1 KR102089241 B1 KR 102089241B1
Authority
KR
South Korea
Prior art keywords
cancer
measured value
subject
cells
predicting
Prior art date
Application number
KR1020180014177A
Other languages
English (en)
Korean (ko)
Other versions
KR20190094710A (ko
Inventor
신의철
김경환
Original Assignee
한국과학기술원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국과학기술원 filed Critical 한국과학기술원
Priority to KR1020180014177A priority Critical patent/KR102089241B1/ko
Priority to PCT/KR2019/001037 priority patent/WO2019151712A1/fr
Publication of KR20190094710A publication Critical patent/KR20190094710A/ko
Application granted granted Critical
Publication of KR102089241B1 publication Critical patent/KR102089241B1/ko

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1486—Counting the particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020180014177A 2018-02-05 2018-02-05 암 환자에서 면역 치료 효과를 예측하는 방법 KR102089241B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020180014177A KR102089241B1 (ko) 2018-02-05 2018-02-05 암 환자에서 면역 치료 효과를 예측하는 방법
PCT/KR2019/001037 WO2019151712A1 (fr) 2018-02-05 2019-01-24 Procédé de prédiction de l'effet d'une immunothérapie sur un patient atteint d'un cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180014177A KR102089241B1 (ko) 2018-02-05 2018-02-05 암 환자에서 면역 치료 효과를 예측하는 방법

Publications (2)

Publication Number Publication Date
KR20190094710A KR20190094710A (ko) 2019-08-14
KR102089241B1 true KR102089241B1 (ko) 2020-03-16

Family

ID=67479833

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180014177A KR102089241B1 (ko) 2018-02-05 2018-02-05 암 환자에서 면역 치료 효과를 예측하는 방법

Country Status (2)

Country Link
KR (1) KR102089241B1 (fr)
WO (1) WO2019151712A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102182091B1 (ko) 2019-10-07 2020-11-23 한국과학기술원 면역항암제에 대한 저항성을 예측하는 방법 및 분석장치
KR102371903B1 (ko) * 2019-12-24 2022-03-08 주식회사 테라젠바이오 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 디바이스
KR102395580B1 (ko) * 2020-02-18 2022-05-10 (주)이노베이션바이오 동반진단용 바이오마커 조성물 및 이를 포함하는 동반진단용 키트
KR102428863B1 (ko) 2020-08-11 2022-08-03 서울대학교병원 자가면역 뇌염 발생 가능성 예측을 위한 정보 제공 방법
WO2022145879A1 (fr) * 2020-12-28 2022-07-07 연세대학교 산학협력단 Méthode de criblage d'inhibiteur de point de contrôle immunitaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015182964A (ja) 2014-03-20 2015-10-22 学校法人慶應義塾 加齢又は肥満に伴う慢性炎症の抑制剤、加齢又は肥満に伴う慢性炎症に関連する疾患の治療剤又は予防剤、罹患可能性評価装置及びスクリーニング方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015003416A (es) * 2012-09-17 2015-10-29 Galectin Therapeutics Inc Metodo para mejorar las inmunoterapias especificas en el tratamiento contra el cancer.
BR112015023120A2 (pt) * 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
JP2017507155A (ja) * 2014-03-05 2017-03-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置
MX2016014753A (es) * 2014-05-15 2017-03-06 Bristol Myers Squibb Co Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015182964A (ja) 2014-03-20 2015-10-22 学校法人慶應義塾 加齢又は肥満に伴う慢性炎症の抑制剤、加齢又は肥満に伴う慢性炎症に関連する疾患の治療剤又は予防剤、罹患可能性評価装置及びスクリーニング方法

Also Published As

Publication number Publication date
KR20190094710A (ko) 2019-08-14
WO2019151712A1 (fr) 2019-08-08

Similar Documents

Publication Publication Date Title
Zhang et al. Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
KR102089241B1 (ko) 암 환자에서 면역 치료 효과를 예측하는 방법
Friedlaender et al. New emerging targets in cancer immunotherapy: the role of TIM3
Chen et al. BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19 high B lymphocytes
Soo et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions
Sgambato et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): a review on toxicity profile and its management
Pianko et al. Immune checkpoint blockade for hematologic malignancies: a review
Okiyama et al. Immune-related adverse events in various organs caused by immune checkpoint inhibitors
Shen et al. The efficacy of third generation anti‑HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells
Harris et al. Immuno-oncology combinations: raising the tail of the survival curve
Merelli et al. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities
Lee et al. Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes
Tarhini Tremelimumab: a review of development to date in solid tumors
Huang et al. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity
JP2020011984A (ja) 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ
Urwyler et al. Mechanisms of checkpoint inhibition-induced adverse events
Bell et al. OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment
Alteber et al. Therapeutic targeting of checkpoint receptors within the DNAM1 axis
Alme et al. Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview
KR20150042784A (ko) Ｃａｒ의 항-종양 활성에 대한 독성 관리
HUE035503T2 (en) Combination of anti-anti-antibodies and anti-PD-1 antibodies to treat cancer
EP3793598A1 (fr) Méthodes de traitement du cancer
Borrie et al. T Lymphocyte–Based Cancer Immunotherapeutics
Stagg et al. Immunomodulation via chemotherapy and targeted therapy: a new paradigm in breast cancer therapy?
CN114174538A (zh) 适合于免疫肿瘤学疗法的多肿瘤基因特征

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant